Current News

Contact | Print version | PDF version | Send article | RSS-Feed

DIREVO announces transfer of patents from Evotec

11 Jul 2008 - DIREVO Biotech AG announced that it has entered into an agreement with Evotec under which Evotec will transfer certain patents to DIREVO that are currently licensed by DIREVO. Such patents protect key components of DIREVO's unique and proven protein/strain engineering platform. Using this platform, DIREVO develops products both independently and with global leaders such as AstraZeneca/MedImmune and Pfizer, as well as Danisco/Genencor and Nestlé.
 
"This is a very important milestone for the company, because DIREVO now owns essential parts of intellectual property protecting its technology" said Dr. Thomas von Rüden, CEO of DIREVO. "This will give us much greater flexibility in the company's future corporate development, e.g., it will allow us to spin out legal entities able to focus and further develop and customize the technology in their own markets"